Annovis (ANVS) Secures Patent Coverage for Both Forms of Buntanetap

Annovis Bio, Inc. (NYSE:ANVS) is one of the best meme stocks. On August 7, Annovis announced that it has finished transferring patents for both the older semi-crystalline and the newer crystalline versions of its drug candidate, buntanetap. These patents will now protect the drug until 2046.

In its press release, Annovis said it has grown its patent portfolio beyond the first patent to also cover the drug’s makeup, how it works, the different diseases it could treat, and how it might be used with other medicines.

The company added that tests on both animals and humans showed the two forms of buntanetap worked the same in the body, with equal exposure levels. These results were shared at the 2025 Alzheimer’s Association International Conference in Toronto.

The FDA has already approved the new crystalline form for Annovis’s ongoing Phase 3 trial in early Alzheimer’s disease. This trial, which started earlier this year, is taking place at over 75 sites in the US and gives participants either a daily dose of the crystalline drug or a placebo for 18 months. Annovis is working on buntanetap as a treatment for neurodegenerative diseases, focusing on its ability to tackle multiple disease processes at the same time.

Annovis Bio, Inc. (NYSE:ANVS), a drug company based in Malvern, Pennsylvania, works on developing treatments for neurodegenerative diseases.

While we acknowledge the potential of ANVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Dow 20 Stocks List: Ranked By Hedge Fund Bullishness Index and 10 Unstoppable Dividend Stocks to Buy Now.

Disclosure. None.